The company develops an implantable left ventricular assist device (LVAD) driven by its proprietary breakthrough wave membrane technology.
In vivo studies demonstrated the pump’s successful operation for six months. Additionally, the company reported nine chronic ovine implants over 60 days with no chronic anticoagulant therapy.
Clichy, France-based CorWave reported no device failure in the studies and no sign of thrombosis at explant. The device operated in pulsatile mode, synchronizing with the native heart rate. Studies underpinned the device’s thromboresistance, stable algorithm and hemocompatibility.
CorWave said the results mark the final stage of CorWave’s preclinical development, paving the way for a first-in-human study. The pumping mechanism, paired with a smart algorithm, enables the pump to adapt its flow to patient activity levels. It preserves physiological balance to reduce adverse events and improve quality of life.
Dr. Martin Strueber, a cardiac surgeon, said in a news release that the technology could “shape the future of long-term mechanical circulatory support.” Strueber says it could overcome current limitations of rotary blood pumps and create real smart and adaptive circulatory support.
“These results not only meet the highest standards in the LVAD industry but also indicate potential clinical advantages over rotary blood pumps that have been in use since the late 1990s. Following these significant milestones, the team is now actively preparing for the clinical introduction of the device,” said Louis de Lillers, CEO.
